Gastric cancer treatment: recent progress and future perspectives
WL Guan, Y He, RH Xu - Journal of hematology & oncology, 2023 - Springer
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …
Current treatment and recent progress in gastric cancer
SS Joshi, BD Badgwell - CA: a cancer journal for clinicians, 2021 - Wiley Online Library
Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …
most common causes of cancer death worldwide. Biological differences between tumors …
Japanese gastric cancer treatment guidelines 2021
Japanese Gastric Cancer Association jgca@ koto. kpu … - Gastric Cancer, 2023 - Springer
The sixth edition of the Japanese Gastric Cancer Treatment Guidelines was completed in
July 2021, incorporating new evidence that emerged after publication of the previous …
July 2021, incorporating new evidence that emerged after publication of the previous …
Japanese gastric cancer treatment guidelines 2018
Japanese Gastric Cancer Association jgca@ koto. kpu … - Gastric cancer, 2021 - Springer
The 5th edition of the Japanese Gastric Cancer Treatment Guidelines was completed in
January 2018, incorporating new evidence that emerged after publication of the previous …
January 2018, incorporating new evidence that emerged after publication of the previous …
Signaling pathways and therapeutic interventions in gastric cancer
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced …
PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally
advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative …
advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative …
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
FH Wang, XT Zhang, YF Li, L Tang, XJ Qu… - Cancer …, 2021 - Wiley Online Library
There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …
tumor biological characteristics, treatment patterns, and drug selections between gastric …
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Gastric cancer is a major source of global cancer mortality with limited treatment options and
poor patient survival. As our molecular understanding of gastric cancer improves, we are …
poor patient survival. As our molecular understanding of gastric cancer improves, we are …
Gastric cancer
Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO …
Purpose The second planned interim analysis (median follow-up 12.5 months) in a phase III
trial of postoperative adjuvant chemotherapy for stage III gastric cancer revealed significant …
trial of postoperative adjuvant chemotherapy for stage III gastric cancer revealed significant …